US 12,678,413 B2 · Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases

Abstract

The present invention relates to compositions containing a pterosin compound and derivatives thereof as active ingredients for the prevention or treatment of degenerative brain diseases and, more specifically, to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases and a food composition for the prevention or alleviation of degenerative brain diseases, each of which contains a pterosin compound defined by chemical formula 1 or a derivative thereof as an active ingredient. A method of the present invention can be favorably used to provide a therapeutic agent for preventing or treating degenerative brain diseases, a food for alleviating degenerative brain diseases, or a functional food for the promotion of cognitive functions, by using a pterosin compound extracted from Pteridium aquilinum and derivatives thereof.

Claims1

Dependent claims

A method for treating or alleviating Alzheimer's disease in a human, the method consisting essentially of administering to the human in need thereof a therapeutically effective amount of a purified composition from a bracken fern consisting of a compound defined by Chemical Formula 1 or a salt thereof as an effective ingredient:

wherein,
R1, R2, R3, R4, R5, R6, and R8 are each independently H, OH, an alkyl or alcohol of 1 to 4 carbon atoms, or alkyl-O-glucose;
and
R7 is one selected from the group consisting of halogen, H, OH, O-alkyl, O-alkenyl, O-alkynyl, O-alcohol, O-carboxyl, O-ether, O-sulfonic acid (—SO3H), O-cycloalkyl, O-heterocycloalkyl, glucose, and O-glucose,
wherein the compound is selected from the group consisting of (2R)-Pterosin B, (2R,3R)-Pterosin C, (2S,3R)-Pterosin C, (2R)-Pteroside B, (2S,3R)-Pteroside C, (2R,3R)-Pteroside C, (3R)-Pterosin D and (3S)-Pteroside D.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/622,799Filed 20 Oct 2017

Priority

KR 10-2017-007670116 Jun 2017

Published

US 2022/0257532 A118 Aug 2022

Granted

14 Jul 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/122
Ketones: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A23L 33/10
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: using additives
A61K 31/045
Medicinal preparations containing organic active ingredients: hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases

Life of this patent

Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases

Life of this patent

Abstract

Claims1